Cargando…

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms

Detalles Bibliográficos
Autores principales:	Hutterer, Evelyn, Asslaber, Daniela, Caldana, Chiara, Krenn, Peter W, Zucchetto, Antonella, Gattei, Valter, Greil, Richard, Hartmann, Tanja N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406159/ https://www.ncbi.nlm.nih.gov/pubmed/25322676 http://dx.doi.org/10.1111/bjh.13188

Ejemplares similares

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells
por: Hofbauer, Sebastian W., et al.
Publicado: (2015)

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21
por: Ganghammer, Sylvia, et al.
Publicado: (2015)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia
por: Haerzschel, Andrea, et al.
Publicado: (2016)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
por: Szenes, Eva, et al.
Publicado: (2020)

Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
por: Greil, Richard, et al.
Publicado: (2017)

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
por: Amrein, Lilian, et al.
Publicado: (2009)

Expert consensus on the management of chronic lymphocytic leukaemia in Asia
por: Tse, Eric, et al.
Publicado: (2023)

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
por: Gassner, Franz Josef, et al.
Publicado: (2010)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020)

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
por: Wierda, William G., et al.
Publicado: (2018)

Comment on ‘Anthropometric measurements and survival after prostate cancer diagnosis’
por: Dal Maso, Luigino, et al.
Publicado: (2018)

The t(11;14)(q13;q32)/CCND1–IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course
por: Liu, Ying, et al.
Publicado: (2019)

Chronic Lymphocytic Leukaemia: Rare Involvement of the Central Nervous System
por: Amado, Carolina, et al.
Publicado: (2021)

The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia
por: Gutjahr, Julia Christine, et al.
Publicado: (2015)

Recurrent histone mutations in T‐cell acute lymphoblastic leukaemia
por: Collord, Grace, et al.
Publicado: (2018)

Molecular characterization and clonal evolution in Richter transformation: Insights from a case of plasmablastic lymphoma (RT‐PBL) arising from chronic lymphocytic leukaemia (CLL) and review of the literature
por: Ramsey, Megan C., et al.
Publicado: (2023)

Genome-wide DNA methylation profiling predicts relapse in childhood B-cell acute lymphoblastic leukaemia
por: Sandoval, Juan, et al.
Publicado: (2013)

p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia
por: Groves, M J, et al.
Publicado: (2013)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia
por: Murali, Aarya, et al.
Publicado: (2021)

A Case of Lymphocytic Leukæmia
por: Reynolds, Fredrick H.
Publicado: (1933)

The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
por: Brachtl, Gabriele, et al.
Publicado: (2013)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model
por: Kocher, T, et al.
Publicado: (2016)

Expression and prognostic analyses of ITGA11, ITGB4 and ITGB8 in human non-small cell lung cancer
por: Wu, Pancheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ia7sc3e5aojoh6uhl3lcikukmu